QUEST DIAGNOSTICS INC
No SEC Form 4 filings for $DGX in the last 30 days.
See all $DGX insider activity →Quest Diagnostics (DGX) announced Catherine T. Doherty will become EVP on November 1, 2026, and retire in July 2027. She will oversee health systems, a joint venture with Corewell Health, and Project Nova. Her base salary remains $650,000, with an $1.2M equity award planned.
QUEST DIAGNOSTICS INC (DGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July
Quest Diagnostics (DGX) reported high accuracy for its Haystack MRD liquid biopsy test across 23 solid tumor types, according to a Journal of Molecular Diagnostics study. The test could impact oncology monitoring and payer decisions. Analysts see potential for revenue growth but note reimbursement risks. Current forecasts predict $13.3B revenue and $1.5B earnings by 2029.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning DGX (QUEST DIAGNOSTICS INC). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent DGX coverage spans financial news, market movers and technology.
The executive change is a routine leadership transition with limited immediate market impact.
Executive transition with no change to compensation suggests limited immediate market impact.
Validation may boost investor confidence in Quest's oncology testing segment.
Positive trial data may improve market perception of Quest Diagnostics' growth prospects in liquid biopsy services.
Positive clinical validation may boost demand for Quest's liquid biopsy services.
AlphAI scores every news story that mentions DGX with an AI model for sentiment and relevance, and aggregates insider trades from QUEST DIAGNOSTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Quest Diagnostics (DGX) announced Catherine T. Doherty will become EVP on November 1, 2026, and retire in July 2027. She will oversee health systems, a joint venture with Corewell Health, and Project Nova. Her base salary remains $650,000, with an $1.2M equity award planned.
1 min readQUEST DIAGNOSTICS INC (DGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July
1 min readQuest Diagnostics (DGX) reported high accuracy for its Haystack MRD liquid biopsy test across 23 solid tumor types, according to a Journal of Molecular Diagnostics study. The test could impact oncology monitoring and payer decisions. Analysts see potential for revenue growth but note reimbursement risks. Current forecasts predict $13.3B revenue and $1.5B earnings by 2029.
2 min readQuest Diagnostics (DGX) reported high accuracy of its Haystack MRD test in detecting residual and recurrent disease in colorectal cancer and other solid tumors. The study showed 100% sensitivity and specificity at three years, and 83.3% sensitivity at five years. DGX is trading at $233.33, 18.5% above its GF Value™ of $196.83, indicating modest overvaluation.
3 min readQuest Diagnostics' Haystack MRD® test showed 100% specificity and high sensitivity in detecting colorectal cancer recurrence, per a study in The Journal of Molecular Diagnostics. The test, using circulating tumor DNA, outperformed standard biomarkers and validated its performance across 23 solid tumor types. Quest Diagnostics is the provider of the test.
2 min readQuest Diagnostics (DGX) received New York State approval to commercialize its molecular residual disease cancer test nationwide. The company is seeing strong momentum in advanced diagnostics and AI-driven automation. Analysts project revenues of $13.3B and earnings of $1.5B by 2029, with a 4.8% yearly revenue growth rate. Key risks include reimbursement pressure and cost inflation.
3 min readLennar rose 4% after Berkshire Hathaway bought 2.7M shares. Amgen gained 3% on positive trial results. Grab Holdings jumped 7% after CEO's share purchase. Capri rose 7% amid potential buyout talks. Shopify gained 7% with Meta AI integration. Quest Diagnostics and Labcorp dropped 5.3% and 3.6% on Medicare payment changes. Vicor rallied 14% on strong Q3 guidance. On Holding jumped 10% on new financial targets. GameStop gained 4% after CEO's share purchase.
3 min readShares of Labcorp (LH) and Quest Diagnostics (DGX) fell 5.9% and 6.9% respectively in premarket trading after CMS proposed cuts to Medicare payment rates for lab services, aiming to save $1B annually and align with private-sector rates. Final 2027 rates will be set in November and take effect January 1, 2027.
2 min readUS futures are flat after a strong prior session, with tech and chipmakers advancing. Alibaba (BABA) rises 3% on AI chip launch. GameStop (GME) +4%, Grab (GRAB) +6%, Quest Diagnostics (DGX) -6%, Vicor (VICR) +9%, Viking Therapeutics (VKTX) +32%. Oil drops after Iran's Hormuz proposal. Treasury yields fall to 4.93%. Trump's UN address awaited.
3 min readAlibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.
2 min read
